Should I snap up Haleon shares at £3?

Haleon shares could provide a reliable stream of dividends for many years, says Roland Head.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Haleon (LSE: HLN) shares dropped straight into the FTSE 100 when they hit the market on 18 July. This £27bn spin-off from pharmaceutical giant GSK is the new owner of consumer healthcare brands such as Sensodyne, Voltaren, Panadol,and Theraflu.

History suggests consumers tend to stay loyal to healthcare brands in a recession, rather than trading down to cheaper options. I reckon Haleon could be a great long-term investment for my portfolio. With the stock hovering around the £3 mark, should I buy?

Why Haleon should be a cash machine

Although Haleon’s advertising focuses heavily on its scientific credentials, the reality is that this business is all about marketing and brands.

Most of Haleon’s core products have been largely unchanged for years. The company only spent £257m on research and development last year. That’s just 2.7% of its £9,545m turnover.

In comparison, I estimate that GSK’s pharmaceutical business spent around 20% of its turnover on R&D last year, excluding Haleon.

To sum up, Haleon has a portfolio of strong brands, which generate consistent sales and have low R&D costs. This is why I believe this business is a cash machine that could generate rising dividends for many years to come.

Will the share price keep falling?

Newly-listed companies are often priced quite high in my experience, so it can pay to be patient.

Haleon seems to be following this pattern, at least so far. The stock listed at 330p, but is down by 12% at 290p as I write.

Another possible reason to be cautious about buying the shares is that US pharmaceutical firm Pfizer is now planning to sell its 25% stake in Haleon.

Pfizer has promised to sell the shares in an orderly way, but it will need to find buyers for nearly £7bn of stock.

What may happen is that if big funds want to buy Haleon, they’ll buy from Pfizer rather than buying in the market. That could leave Haleon’s share price struggling for support.

Haleon shares: what I’m doing

A post-pandemic surge in cold and flu infections is expected. That would be good news for Haleon, whose portfolio includes several popular cold and flu medicines.

However, although I expect Haleon’s cash generation to be strong this year, the stock’s forecast dividend yield is just 1.1%. This figure rises to 2.1% for 2023, but that’s still pretty low.

The main reason for this low yield is that cash is required to reduce the £10bn debt pile Haleon inherited from GSK. I don’t think this will be too much of a problem, but CEO Brian McNamara expects to need three years to bring leverage down to target levels.

I think Haleon shares could offer long-term value at current levels. But in my view, the combination of the Pfizer share sale and the stock’s low dividend yield could mean that the Haleon’s share price drifts lower over the coming months.

For these reasons, I’m going to wait a little longer before deciding whether to buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »